40 results about "Salivary Proteins" patented technology

The relates to an agglutinin chip used for identifying cancer, in particular to an agglutinin chip for identifying breast cancer based on sialoprotein, a reagent kit and application of the reagent kit, and aims at providing an agglutinin chip for identifying breast cancer in a non-destructive mode through the change of carbohydrate chains in saliva, a reagent kit and application of the reagent kit. The agglutinin chip for identifying breast cancer based on sialoprotein comprises an agglutinin testing probe set. The agglutinin testing probe set at least comprises a combination of PHA-E+L, LTL, BS-I, MAL-I, LCA, BPL, PTL-II, NPA and GSL-I, or at least comprises a combination of LTL, BS-I, MAL-I, LCA, BPL, NPA and GSL-I. By means of the agglutinin chip, differentially-expressed glycoprotein carbohydrate chain structures in a patient saliva sample can be rapidly detected, whether a corresponding person suffers from a breast tumor or not is detected, and whether the breast tumor is breast cancer or not is determined; besides, saliva is adopted as an object to be detected and is easy and convenient to collect, and health risks existing when a serum sample is collected for detection in the prior art are avoided.

The invention discloses a salivary protein diagnosis model for gastric cancer and an establishment method for the salivary protein diagnosis model. The establishment method for the salivary protein diagnosis model for gastric cancer comprises the following steps of collecting and processing a saliva sample; processing the saliva sample by adopting WCX magnetic balls; performing sample application and mass spectrometry; and performing data statistical analysis. The salivary protein diagnosis model for gastric cancer mainly comprises four salivary protein peaks, and mass-to-charge (m/z) ratios of the salivary protein peaks in human salivary proteins are 1,472.78Da, 2,936.49Da, 6,556.81Da and 7,081.17Da respectively. According to the salivary protein diagnosis model for gastric cancer and the establishment method for the salivary protein diagnosis model, by a classification prediction model established by the four protein peaks of which the mass-to-charge ratios (m/z) in the human salivary proteins are 1,472.78Da, 2,936.49Da, 6,556.81Da and 7,081.17Da respectively, the m/z of the corresponding proteins in human saliva and the model are analyzed to preliminarily judge gastric cancer, the identification rate is 97.83 percent, and the predication capability is 79.82 percent. Clinical back substitution test results show that the accuracy rate of the diagnosis model is 97.56 percent, the sensitivity of the diagnosis model is 95.65 percent and the specificity of the diagnosis model is 100 percent. The establishment method is simple, and has the characteristics of reasonability, feasibility, convenience in operation and batch processing capability.

The invention provides a lectin chip for detecting carbohydrate chain markers based on protein in blood serum or saliva as well as a kit and application of the lectin chip, relates to the lectin chip for detecting the carbohydrate chain markers in blood serum or saliva, and particularly relates to the lectin chip for detecting the carbohydrate chain markers based on protein in blood serum and saliva as well as a kit and application of the lectin chip. The invention aims at providing a non-injury lectin chip for detecting the carbohydrate chain markers by identifying protein in saliva or blood serum and a method thereof. The lectin chip for detecting the carbohydrate chain markers based on serum carbohydrate binding protein, provided by the invention, comprises a testing lectin probe set, wherein the testing lectin probe set at least comprises PTL-I, PNA, AAL, LTL, STL, BS-I, PTL-II, SBA, ACA, UEA-I, MAL-I and PHA-E+L. The lectin chip can be used for rapidly detecting a specific carbohydrate protein chain structure in blood serum and saliva samples, and rapidly judging the specific combination of carbohydrate chains in the samples, so as to determine whether corresponding people have hepatitis or not and determine whether people are ACHBLF patients or not.

Provided herein is an all-in-one saliva collection apparatus that collects saliva to allow for the filtration of saliva in order to separate saliva components, such as extracellular proteins and nucleic acids that are not present in intact cells, from the intact cells and debris remaining in the extracted sample. The filtered saliva samples can be aliquoted into two fractions for protein and/or nucleic acid analysis. The present invention further describes long term storage at ambient temperatures of filtered salivary nucleic acids, and long term storage at ambient temperatures of filtered salivary proteins added to an ethanol solution. The filtered cell-free saliva samples have diagnostic usefulness.

The invention provides a transgenic animal having within its genome a transgene construct for gastrointestinal tract specific expression of a protein. In a preferred embodiment, the protein is a phytase or a homologue thereof. Such proteins may be heterologous and may be specifically expressed in the salivary gland of the animal by operably linking the nucleic acid sequence encoding the protein with regulatory sequence including a salivary gland protein promoter/enhancer. Also provided are methods of expressing and producing proteins using such nucleic acid constructs. Further, antibodies specific to such proteins and immunological diagnostic kits are also provided.

The present invention provides for the first time the identification of salivary protein and RNA factors that can be used in the detection of diabetes. The present invention therefore provides methods of diagnosing and providing a prognosis for diabetes, by examining relevant proteins and RNA in a patient's saliva.

The invention discloses a bionic anti-caries functional polypeptide based on casein-rich saliva, a polypeptide derivative or a pharmaceutically acceptable salt and an application in pharmacy thereof. The bionic anti-caries functional polypeptide is based on an anti-caries functional segment of the casein-rich saliva, the adjustment and improvement for the amino acid sequence are performed on the anti-caries functional segment and the bionic anti-caries functional polypeptide contains the amino acid sequence shown as SEQ ID NO.1. The polypeptide mainly utilizes the 'DpSpSEEK' amino acid sequence to realize the adsorption combination of polypeptide and de-mineralized enamel and the 'DpSpSEEK' amino acid sequence thereof can react with calcium phosphate ions so as to induce hydroxyapatite nucleation, so that the in-situ mineralizing repairing function for early enamel caries can be realized. The polypeptide is characterized by lower molecular weight, convenience in compound, low cost, better anti-caries effect, structure stability, safety and reliability. The invention utilizes the bionic thought to simulate natural saliva protein, designs the anti-caries polypeptide with a re-mineralization function and provides an ideal new method for preventing and controlling caries.

The invention discloses a detection method of diabetes B kidney deficiency salivary protein markers. The method comprises the following concrete steps of extracting sample protein; determining the extracted protein concentration by a Bradford method; performing proteolysis, iTRAQ marking, vacuum freeze centrifugation drying and reversed-phase chromatography separation under high pH conditions; performing protein analysis on ABI-5600; performing mass spectrometric data analysis; during database selection, if organisms are sequenced organisms, directly selecting the species databases; if the organisms are non-sequenced organisms, selecting main category proteome database most relevant to the tested sample; using an ABI-5600 type mass spectrograph to perform iTRAQ mass spectrograph analysis.The specific protein marker in the diabetes B kidney deficiency can be fast and reliably discovered by a proteomic technological scheme. A noninvasive, simple, convenient, fast and practical detectionand evaluation measure is built for the early diagnosis and treatment, postoperative recurrence, transfer and prognosis observation of the diabetes B kidney deficiency.

A method of diagnosing a patient's risk of breast cancer comprises measuring in a saliva sample from the patient a concentration of at least a first protein marker, wherein the first protein marker is either ubiquitin or cytochrome p450, to provide a set of test data comprising a concentration value of each protein marker in the saliva sample. The test values are then compared to a reference panel comprising a Reference Control Value and a Reference Breast Cancer Value, and a diagnosis of either increased or decreased risk of breast cancer is determined for the patient based on a result of that comparison. A test kit for identifying a person at increased risk of breast cancer is also provided.

The invention relates to an in-vitro method for representing the influence of cigarette smoke on oral astringency, and belongs to the technical field of biological application. The method includes thesteps of cigarette main stream smoke total particulate matter extraction, artificial saliva preparation, TPM supernatant preparation, dyeing, protein content measurement and the like. The method is simple in operation, a protein environment in saliva is simulated by salivary amylase according to the principle that astringency can be generated by salivary protein precipitation, and astringency isquantitatively represented by precipitation proportion. Moreover, smoke total particulate matters are gathered by in-vitro suction and then react with the salivary amylase, the influence of smoke on the salivary amylase is amplified by the concentration process, subtle differences of different cigarette smoke are compared, and the method can be used for quantitative representing the influence of the cigarette smoke on oral astringency and provides a reference for sensory evaluation of the cigarette smoke.

It is generally accepted that salivary components are important for dental health, but till now no clear correlation has been found between one or more of said components and the onset of dental caries. The present invention relates to an assay method comprising analysing the presence and/or the content of the salivary soluble CD14 protein from a saliva sample of the individual subjected to examination; the absence of said protein from the salivary sample, or its presence in a reduced amount compared to a predetermined threshold value in caries-free individuals, is considered as a marker of susceptibility to developing caries and/or as a diagnostic element for the existence of ongoing carious lesions.

The invention provides an attractant for promoting salivary protein secretion of mycophagous flour mites, and a salivary protein collection method. The attractant comprises a solvent and an attractant component dissolved in the solvent; the solvent comprises a sucrose aqueous solution; and the attractant component is prepared from 3-octanone and alpha-terpinene. According to the attractant for promoting salivary protein secretion of the mycophagous flour mites, provided by the invention, through the synergistic effect of the sucrose aqueous solution, the 3-octanone and the alpha-terpinene, the mycophagous flour mites are attracted by utilizing the volatility of the 3-octanone and the alpha-terpinene; and 3-octanone, alpha-terpinene and the sucrose aqueous solution are used for stimulating the lured mycophagous flour mites to secrete salivary proteins, so that the secretion amount of the salivary proteins is increased, and the difficulty of obtaining the flour mite salivary protein is reduced.

The invention discloses a method for establishing a type 2 diabetes salivary protein fingerprint molecular diagnostic model, comprising the following steps: sample collection; sample pretreatment; nano magnetic beads activation; saliva sample loading; nano magnetic beads elution; data collection; analysis; building diagnostic models. The present invention uses a liquid chip combined with MALDI technology to detect the saliva protein fingerprints of patients with type 2 diabetes, screens out 80 highly significant statistically significant differential protein peaks from the saliva proteins, and selects mass-to-charge ratios of 2082.92, 2499.24 and 2426.77 Differential protein peaks were modeled, with a recognition rate of 94.3% and a predictive ability of 93.3%. The results of clinical back substitution test showed that the sensitivity of the diagnostic model was 88.6%, and the specificity was 77.8%. It shows that the model has excellent diagnostic efficiency, high sensitivity and strong specificity for type 2 diabetes.